BioventixFRA:51B -1.13%64 EV-to-FCF is 9.89 as of Jul. 09, 2026, which is 64% below its 10-year median of 27.26. GuruFocus rates FRA:51B with a GF Score™ of 64/100 and a GF Value™ of €38.68 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 327 Biotechnology companies, Bioventix ranks better than 60.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioventix's Enterprise Value is €88.94 Mil.
Bioventix's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €9.00 Mil. Therefore, Bioventix's EV-to-FCF for today is 9.89.
The historical rank and industry rank for Bioventix's EV-to-FCF or its related term are showing as below:
FRA:51B'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.65 Med: 27.26 Max: 37.96
Current: 10.08
During the past 13 years, the highest EV-to-FCF of Bioventix was 37.96. The lowest was 9.65. And the median was 27.26.
FRA:51B's EV-to-FCF is ranked better than 60.55% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs FRA:51B: 10.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioventix's share price for today is €17.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioventix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.631.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioventix EV-to-FCF Related Terms
Bioventix EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioventix's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bioventix's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioventix's EV-to-FCF falls into.
Bioventix's current Enterprise Value is €88.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioventix's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €9.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (FRA:51B) has a EV-to-FCF of 9.89 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioventix and its competitors. This is 64% below median its historical median of 27.26. Over the past decade, Bioventix's EV-to-FCF has ranged from 9.65 to 37.96. According to the industry distribution chart, Bioventix ranks #129 out of 327 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Bioventix's EV-to-FCF too high?
Bioventix's current EV-to-FCF of 9.89 is 64% below median its 10-year median of 27.26. Over the past 10 years, this metric has ranged from a low of 9.65 to a high of 37.96. The Biotechnology industry median EV-to-FCF is 16.69. Bioventix's value of 9.89 is 40.7% below this industry median. Based on the distribution chart, Bioventix ranks #129 out of 327 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bioventix has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #129 out of 327 companies for EV-to-FCF. This puts Bioventix in the upper half of its industry. The industry median EV-to-FCF is 16.69. Bioventix's value of 9.89 is 40.7% below this benchmark. Historically, Bioventix's own EV-to-FCF has ranged from 9.65 to 37.96 over the past decade. While the company's 10-year median is 27.26 vs. the industry median of 16.69, Bioventix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioventix's current EV-to-FCF of 9.89 is 40.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioventix and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventix's current EV-to-FCF is 9.89, which is 64% below median its own 10-year median of 27.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (FRA:51B) is currently considered Significantly Undervalued. The stock's GF Value™ is €38.68, compared to a current price of €17.50 — trading 54.8% below its estimated fair value. The current EV-to-FCF is 9.89, which is 64% below median its 10-year median of 27.26 and 40.7% below the Biotechnology industry median of 16.69. Bioventix's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioventix (FRA:51B), the current EV-to-FCF is 9.89 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (FRA:51B) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of €17.50 is trading 54.8% below its estimated GF Value™ of €38.68.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for FRA:51B:
EV-to-FCF: 9.89 (64% below median its 10-year median of 27.26)
GF Value™: €38.68 vs. price of €17.50 (54.8% below fair value)
Industry Position: 40.7% below the Biotechnology median (#129 of 327)
No single metric tells the full story. See the FRA:51B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
64GF Score
Get the complete analysis for FRA:51B
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:51B has been successfully added to your 
